DJ
Dragan Jevremovic
Research areas: Medicine · Hematology · Multiple Myeloma Research and Treatments · Chronic Lymphocytic Leukemia Research · Lymphoma Diagnosis and Treatment
0000-0002-1792-5822
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (114)
- Spatial profiling of extramedullary multiple myeloma demonstrates immune-excluded and suppressive tumor microenvironment Save
- Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s) Save
- Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia Save
- Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma Save
- Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma Save
- Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia Save
- Immunoglobulin Light Chain Amyloidosis Save
- Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple Myeloma Save
- Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma Save
- Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia Save
- Clinical and Prognostic Impact of Allelic Status in EZH2‐Mutated Myeloid Neoplasms Save
- Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes Save
- Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia Save
- Predictors of Local Control With Palliative Radiotherapy for Multiple Myeloma Save
- Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma Save
- Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms Save
- FDA IDE validation of multiple myeloma MRD test by flow cytometry Save
- Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma Save
- Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms Save
- Characterisation and prognostic impact of ZRSR2 mutations in myeloid neoplasms Save